Tirzepatide to Slow Biological Aging

NCT07220473 · Recruiting

Last updated 2026-05-28

This clinical trial is testing whether the medication tirzepatide can slow biological aging in adults by measuring changes in DNA methylation-based biological age.

Status Recruiting Currently enrolling participants.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, double-blind prevention study

Participants 90 people Planned (estimated).

Who can join Ages 55–70 · all sexes

Timeline Started 2026-02 · est. completion 2028-01

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT07220473 ↗

Description as written by the study sponsor.

This pilot clinical study aims to investigate the potential effects of tirzepatide on biological aging in older adults. In this novel study, 90 adults aged 55-70 years with an indication for tirzepatide weight-loss therapy will be randomized to receive either tirzepatide 2.5 mg subcutaneously (SC) weekly or no drug for 24 weeks, followed by 12 weeks off the drug. Since tirzepatide is already recognized as a highly effective weight-loss agent in this population, the primary focus will not be on measuring weight loss. Instead, the study will document the effects of tirzepatide on markers of aging, physical function, and overall health.

Treatments tested

Zepbound also known as Tirzepatide Drug

Auto injectors with a 2.5 mg dosage are given subcutaneously weekly.

Main thing measured	Change in DNA Methylation-Based Biological Age
Sponsor	The University of Texas Medical Branch, Galveston
Conditions studied	Aging, LONGEVITY 1
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07220473 ↗